WASHINGTON, DC - Energy and Commerce Committee Chairman Greg Walden (R-OR) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX) today issued the following statement after President Trump’s speech on drug pricing reforms.
“We applaud President Trump and his team for taking on the issue of high drug costs. As we saw firsthand during a December 2017 Health Subcommittee hearing reviewing the drug supply chain, everyone has a role in this process and it’s important that we do everything we can to responsibly squeeze out excess costs and put the consumer first. The Energy and Commerce Committee has taken a number of steps to spur innovation and increase competition - advancing key priorities that are now law, including the 21st Century Cures Act, and a reauthorization of the generic drug user fee program in the FDA Reauthorization Act. We appreciate President Trump’s interest and commitment in working to lower the cost of important medications and critical care and services, and look forward to working with him to continue to do so."
